NO20000439L - Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyreforbindelser samt metoder for behandling av hyperlipidemi - Google Patents

Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyreforbindelser samt metoder for behandling av hyperlipidemi

Info

Publication number
NO20000439L
NO20000439L NO20000439A NO20000439A NO20000439L NO 20000439 L NO20000439 L NO 20000439L NO 20000439 A NO20000439 A NO 20000439A NO 20000439 A NO20000439 A NO 20000439A NO 20000439 L NO20000439 L NO 20000439L
Authority
NO
Norway
Prior art keywords
nicotinic acid
nicotinamide
methyl
hmg
combinations
Prior art date
Application number
NO20000439A
Other languages
English (en)
Other versions
NO20000439D0 (no
Inventor
David J Bova
Josephine Dunne
Original Assignee
Kos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kos Pharma Inc filed Critical Kos Pharma Inc
Publication of NO20000439D0 publication Critical patent/NO20000439D0/no
Publication of NO20000439L publication Critical patent/NO20000439L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Den foreliggende oppfinnelse vedrører faste farmasøytiske kombinasjoner for oral administre- ring som omfatter nikotinsyre eller en nikotinsyreforbindelse eller blandinger derav i en for- lenget frigjørende form og en HMG-CoA reduktaseinhibitor, som er egnet til å endre lipidni- våer i subjekter som lider av eksempelvis hyperlipidemi og aterosklerose, uten å forårsake medisinindusert hepatotoksisitet, myopati eller rabdomyolyse. Den foreliggende oppfinnelse vedrører også fremgangsmåter til endring av serumlipider i subjekter til behandling av eks- empelvis hyperlipedimi i hyperlipidemiske pasienter, lipidemi i normolipidemiske pasienter som er diagnostisert med eller disponert for kardiovaskulær sykdom, og aterosklerose. ved å administrere slike orale faste farmasøytiske kombinasjoner en gang.per.dag som en enkeltdo- - se i løpet av kveldstimene, ulen å forårsake medisinindusert hepatotoksisitet, myopati eller rabdomyolyse, eller uten å forårsake i det minste et påvistbart antall individers medisinindu- serte hepatotoksisitet, myopati eller rabdomyolyse til et slikt nivå at diskontinuering av slik terapi ville måtte kreves. Nærmere bestemt vedrører den foreliggende oppfinnelse orale faste farmasøytiske kombinasjoner som eksempelvis omfatter (1) en HMG-CoA reduktaseinhibitor for umiddelbar eller forlenget frigjøring, (2) nikotinsyre, en nikotinsyreforbindelse eller blan- dinger derav, (3) et svellende agens til dannelse av et forlenget frigjørende preparat for for- lenget frigjøring av nikotinsyren eller nikotinsyreforbindelsen eller blandinger derav for natt- lig eller kveldsdosering til reduksjon av serumlipider og økning av HDL-kolesterol. I sam- svar med den foreliggende oppfinnelse, og som et eksempel, beskrives et preparat for oral administrering i løpet av kveldstimene for endring av serumlipider idet dette består av niko- tinsyre og hydroksypropylmetylcellulose i form av en forlenget eller vedholdende frigjørende tablett eller caplet som er belagt med et belegg som omfatter en HMG-CoA reduktaseinhibitor i umiddelbart frigjørende form. Også i samsvar med den foreliggende oppfinnelse, kan de farmasøytiske kombinasjoner inkludere et ikke stereodalt inflammatorisk agens til reduksjon av nikotinsyrens eller nikotinsyreforbindelenes mulLghet.for å provosere frem rødmingsreak-" '¿ sjoner hos individer.
NO20000439A 1997-07-31 2000-01-27 Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyreforbindelser samt metoder for behandling av hyperlipidemi NO20000439L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90375297A 1997-07-31 1997-07-31
PCT/US1998/015990 WO1999006035A2 (en) 1997-07-31 1998-07-31 COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT

Publications (2)

Publication Number Publication Date
NO20000439D0 NO20000439D0 (no) 2000-01-27
NO20000439L true NO20000439L (no) 2000-03-22

Family

ID=25418027

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000439A NO20000439L (no) 1997-07-31 2000-01-27 Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyreforbindelser samt metoder for behandling av hyperlipidemi

Country Status (17)

Country Link
US (3) US20040053975A1 (no)
EP (2) EP1792616B1 (no)
JP (2) JP4870869B2 (no)
AT (2) ATE359785T1 (no)
AU (1) AU752673B2 (no)
BR (1) BR9815548A (no)
CA (1) CA2298549C (no)
CY (1) CY1107057T1 (no)
DE (2) DE69837610T2 (no)
DK (1) DK1017390T3 (no)
ES (2) ES2336492T3 (no)
HK (1) HK1106153A1 (no)
IL (2) IL134271A0 (no)
NO (1) NO20000439L (no)
NZ (1) NZ520176A (no)
PT (1) PT1017390E (no)
WO (1) WO1999006035A2 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE970731A1 (en) † 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
DE19858789A1 (de) * 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
WO2001005408A1 (en) * 1999-07-14 2001-01-25 Geltex Pharmaceuticals, Inc. Fat-binding polymers, optionally combined with lipase inhibitors
JP2001131151A (ja) * 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
EP1296672B2 (en) † 2000-06-09 2018-10-24 LEK Pharmaceuticals d.d. Stable pharmaceutical product and formulation
CN1250212C (zh) * 2000-10-23 2006-04-12 三共株式会社 血中脂类改善剂组合物
US6916849B2 (en) 2000-10-23 2005-07-12 Sankyo Company, Limited Compositions for improving lipid content in the blood
CA2428204A1 (en) 2000-11-07 2002-05-16 Sankyo Company, Limited Lipid peroxide-lowering compositions
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
CA2494801A1 (en) * 2002-08-02 2004-02-12 Sankyo Company Limited Medicinal composition containing hmg-coa reductase inhibitor
JP4607436B2 (ja) * 2002-08-02 2011-01-05 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
CN100415235C (zh) * 2002-08-02 2008-09-03 三共株式会社 含有HMG-CoA还原酶抑制剂的药物组合物
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP2007501217A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク コレステリルエステル転送タンパク質阻害剤を制御放出し、そしてＨＭＧ−ＣｏＡレダクターゼ阻害剤を即時放出する投薬形態
EP1684704A2 (en) * 2003-10-29 2006-08-02 Raif M. Tawakol Compositions and methods for increasing hdl and hdl-2b levels
EP1877054A2 (en) * 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070021379A1 (en) * 2005-07-11 2007-01-25 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
KR20070063350A (ko) * 2005-12-14 2007-06-19 주식회사종근당 서방형 방출층과 속방형 방출층을 포함한 고지혈증 및동맥경화를 치료를 위한 약제학적 조성물
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
WO2007103557A2 (en) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
DE102007003524A1 (de) * 2007-01-19 2008-09-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose
KR100885029B1 (ko) 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2009016577A2 (en) * 2007-07-27 2009-02-05 Ranbaxy Laboratories Limited A pharmaceutical composition comprising atorvastatin and niacin
KR101164300B1 (ko) * 2008-02-22 2012-07-09 한올바이오파마주식회사 약제학적 제제
KR20090091075A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 심혈관계 질환 치료용 약제학적 제제
JP2011512406A (ja) * 2008-02-22 2011-04-21 ハナル バイオファーマ カンパニー リミテッド 複合製剤
JP2011521915A (ja) * 2008-05-20 2011-07-28 セレニス セラピューティクス エス．エー． ナイアシン及びｎｓａｉｄ併用療法
RU2010153904A (ru) * 2008-06-02 2012-07-20 Др. Редди'С Лабораторис Лтд. (In) Ниацин-содержащие композиции с модифицированным высвобождением
TR201009949T1 (tr) * 2008-06-02 2011-03-21 Dr. Reddy's Laboratories, Ltd. Salımı değiştirilmiş niasin formülasyonları.
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
US8541435B2 (en) 2008-07-11 2013-09-24 Uday Saxena Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)
MX345942B (es) * 2009-05-01 2017-02-27 Adare Pharmaceuticals Inc Composiciones de tabletas que se desintegran oralmente que comprenden combinaciones de farmacos en dosis alta y baja.
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
ES2643693T3 (es) 2011-05-20 2017-11-23 Astrazeneca Uk Limited Composición farmacéutica de rosuvastatina cálcica
JP2017533973A (ja) 2014-11-14 2017-11-16 ジェムフィアー セラピューティクス インコーポレイテッド α，ω−ジカルボン酸末端ジアルカンエーテルを調製するためのプロセスおよび中間体
AU2016348638A1 (en) * 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524001A (en) * 1965-03-04 1970-08-11 Upjohn Co Compositions and method for reducing free fatty acid and cholesterol in the blood of mammals with 3,5 - disubstituted isoxazoles
JPS63310827A (ja) * 1987-06-15 1988-12-19 Sanwa Kagaku Kenkyusho Co Ltd ニコチン酸誘導体を主剤とする徐放性製剤
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US4933165A (en) * 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2018470A1 (en) * 1989-07-17 1991-01-17 Scott Adams Biller Phosphorus-containing squalene synthetase inhibitors and method
WO1993009777A1 (en) * 1991-11-22 1993-05-27 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
US5135935A (en) * 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
US5840339A (en) * 1991-07-30 1998-11-24 Kunin; Robert Blood cholesterol reducing pharmaceutical composition
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
US5773453A (en) * 1995-04-19 1998-06-30 Vanderbilt University Methods for administration of antilipemic drugs

Also Published As

Publication number Publication date
ES2283067T3 (es) 2007-10-16
WO1999006035A3 (en) 1999-04-22
US20040053975A1 (en) 2004-03-18
AU752673B2 (en) 2002-09-26
JP2001511444A (ja) 2001-08-14
CA2298549A1 (en) 1999-02-11
HK1106153A1 (en) 2008-03-07
DE69841395D1 (de) 2010-01-28
DK1017390T3 (da) 2007-06-11
EP1017390B1 (en) 2007-04-18
IL134271A0 (en) 2001-04-30
NO20000439D0 (no) 2000-01-27
PT1017390E (pt) 2007-07-24
EP1792616B1 (en) 2009-12-16
ATE451926T1 (de) 2010-01-15
CY1107057T1 (el) 2012-10-24
EP1017390A2 (en) 2000-07-12
BR9815548A (pt) 2000-11-07
ES2336492T3 (es) 2010-04-13
WO1999006035A2 (en) 1999-02-11
US20120164221A1 (en) 2012-06-28
NZ520176A (en) 2005-02-25
EP1792616A1 (en) 2007-06-06
DE69837610T2 (de) 2008-01-03
AU8680198A (en) 1999-02-22
DE69837610D1 (de) 2007-05-31
JP2009235105A (ja) 2009-10-15
IL134271A (en) 2006-07-05
ATE359785T1 (de) 2007-05-15
US20090226518A1 (en) 2009-09-10
JP4870869B2 (ja) 2012-02-08
CA2298549C (en) 2006-01-10

Similar Documents

Publication Publication Date Title
NO20000439L (no) Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyreforbindelser samt metoder for behandling av hyperlipidemi
HU9202265D0 (en) Wall-mounted disc for joining sanitary equipments onto mounting wall
LU90230I2 (fr) Cerivastatine (INN) et ses sels et dérivés pharmaceutiquement acceptables (LIPOBAY )
AU7756694A (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
AU5683296A (en) N-benzylindol-3-yl propanic acid derivatives as cyclooxygena se-2 inhibitors
CA2356158A1 (en) Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
NO973814L (no) Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor
WO2004052853A3 (en) Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP0773022A3 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
WO2003046034A3 (en) Improved synthesis of polyanhyrides
EE200000659A (et) 4-(3,5-bis-trifluorometüülbensüülamino)-2-etüül-6-trifluorometüül-3,4-dihüdro-2H-kin oliin-1-karboksüülhappe etüülestrid või nende soolad ja valmistamise meetodid
AU6527090A (en) Substituted cyclohexene derivatives as hmg-coa reductase inhibitors
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
PL331339A1 (en) Antihrombotic and antiarteriosclerotic pharmaceutical composition containing derivative of thiene pyridine as well as an inhibitor of hmg-coa reductase
AU3368400A (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease
BR0317520A (pt) Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase
IS2477B (is) Aðferð til að framleiða díoxanediksýruestera
NO20053581L (no) Optisk aktivt dihydropyridinderivat.
NO20021937L (no) Fremgangsmåte for administrering av en fosfodiesterase 4- hemmer
AU4543699A (en) Multibinding inhibitors of hmg-coa reductase
NZ336376A (en) Enzymatic resolution of benzodiazepine-acetic acid esters (3-oxo-2,3,4,5-1H-tetrahydro-1,4-benzodiazepine-2-acetic acid) with a lipase from Candida Antarctica
AU8542498A (en) Derivatives of 1-oxyl-4-hydroxy- or 4-amino-2,2,6,6-tetramethylpiperidine as polymerization inhibitors for (meth)acrylate monomers
DK422989D0 (da) Quinolin- og pyridinankre for hmg-coa-reductaseinhibitorer
WO2004041168A3 (en) Compositions and methods for prevention of photoaging
HUT55009A (en) Process for producing imidazolyl and pyridyl derivatives of phenyl-substituted 1,4-dihydropyridines and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application